

Special Issue

Treatment of Peripheral T-cell Lymphomas

Message from the Guest Editor

peripheral T-cell lymphomas (PTCL) are a clinically and molecularly highly heterogeneous group of rare lymphoid malignancies, that typically share an aggressive clinical behavior and poor prognosis. With current first-line treatment strategies, only a minority of patients can be cured and relapsed-refractory diseases underscore the need for innovative therapeutic strategies. Over the past decade, molecular studies unraveled distinct pathogenic alterations in subgroups of PTCL, providing a basis for both molecular classification and specific therapies addressing the pivotal biology of these diseases. Indeed, upcoming concepts including targeted inhibitors of crucial oncogenic signaling pathways, epigenetic therapeutics as well as immunotherapeutic approaches show promise. Still, tailoring optimal concepts for patients with PTCL remains a significant challenge. This special issue will highlight preclinical and clinical research on therapeutic strategies and biomarkers in PTCL.

Guest Editor

Dr. Raphael Koch

Department of Hematology and Medical Oncology, University of Göttingen, 37075 Göttingen, Germany

Deadline for manuscript submissions

15 October 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/164933

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)